Chemical-structure (Chemical Structure)
Alendronate Sodium
Product Images NDC 50090-1802
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 50090-1802). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure-1 (Figure 1)
The text provides a graphical representation of the cumulative incidence (%) of hip fractures in a three-year study of FIT. The study includes patients with radiographic vertebral fracture at baseline and compares the results between those who received a placebo versus those who received Alendronate Sodium. The graph displays the data over a 36-month period with measurements taken at 6-month intervals.*
Figure2 (Figure2)
Figure3 (Figure3)
This seems to be a graph illustrating the effect of Alendronate on women with osteoporosis over time. The x-axis shows the time frame in months, while the y-axis shows the percent change in bone mineral density (BMD) from baseline. The graph contains data from two studies, a US study and a multinational study. The treatment group received Alendronate 10 mg/day, while the control group received placebo. Overall, the graph shows a significant increase in BMD in the treatment group compared to the control group.*
Figure4 (Figure4)
Figure5 (Figure5)
The text describes a figure (Figure 5) showing the results of studies on the increase in bone mineral density (BMD) in patients treated with glucocorticoids. Specifically, the figure shows the mean percentage increase in BMD relative to a placebo after one year of treatment with alendronate at a dose of 5 mg/day. The results are presented for the lumbar spine, femoral neck, and trochanter. The data appears to come from a multinational study.*
Figure6 (Figure6)
This is a figure showing the effect of Alendronate 40 mg/day on serum alkaline phosphatase in comparison with Placebo and Etidronate 400 mg/day, in a study related to Paget's disease of bone. The figure shows data points for each treatment group at 0, 3, and 6 months. No further information is available.*
Label Image (Lbl500901802)
Label Image (Lbl500901803)
This is a product with code number 6047-6 that contains Alendronate Sodium in the amount of 35 mg per 4 tablets. The product is labeled with "ASH LOT".*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
